CD40 ligand-induced apoptosis is Fas-independent in human multiple myeloma cells.

Abstract:

:We and others previously demonstrated that human multiple myeloma (MM) cells express CD40 and have an active CD40-growth regulatory pathway. This study characterizes the growth outcome of soluble (gp39) or membrane-bound recombinant human CD40-ligand (rCD40L) and its relationship with Fas-dependent apoptosis. Contrary to the moderate growth-stimulatory effect of the CD40-MAb G28.5, gp39 inhibited 3H-thymidine uptake of the plasma dyscrasia lines ARH-77, U266, and HS-Sultan in a dose-dependent fashion by up to 82%. By comparison, RPMI 8226 cells were resistant to CD40L-growth modulation, which may be attributable to a single base substitution (TCA-->TTA, serine-->leucine) at the 3rd cysteine-rich extramembrane region of CD40. Gp39 similarly reduced myeloma clonogenic colony (MCC) formation in patient primary bone marrow cultures by 50% (40-76%; n=6). Studies using transfectant L cells that constitutively expressed CD40L showed that membrane-bound CD40L inhibited the growth of ARH-77, U266, and HS-Sultan cells (66%, 63%, and 32%, respectively), whereas untransfected L cells did not. Growth inhibition by gp39 or CD40L+ L cells was neutralized by coincubation with the CD40L antibodies 5c8 or LL48. CD40L-treatment increased apoptotic activity of MM cells, as defined by oligonucleosomal DNA fragmentation and an increased binding to annexin V (16-28%). All three untreated CD40-responsive MM lines expressed the Fas/Apo-1/CD95 antigen (65-92% CD95+). However, only ARH-77 cells responded to the growth inhibitory effect of the CD95-agonistic antibody CH-11. CD95 expression was not affected significantly by gp39 treatment, and growth inhibition by CH-11 was additive to gp39 (from 42% to 64% decrease in 3H-thmidine uptake). Conversely, the CD95 antagonist antibody ZB4 reversed the Fas-dependent growth inhibitory process but did not significantly alter gp39-mediated growth outcome. Gp39 treatment lowered the expression of TNFR-associated factors TRAF4 and TRAF6 by 38% and 32%, respectively, whereas detectable levels of TRAF1,2,3, and 5 levels remained unchanged. Our observations indicate that the CD40L-binding inhibits human MM cell growth and increases its apoptotic activity. This growth inhibitory effect corresponds to lower levels of cytoplasmic TRAF signaling elements, and appears independent of the Fas-signaling pathway. CD40 receptor mutation may lead to unresponsiveness to CD40 growth modulation in multiple myeloma cells.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Tong AW,Seamour B,Chen J,Su D,Ordonez G,Frase L,Netto G,Stone MJ

doi

10.3109/10428190009148403

keywords:

subject

Has Abstract

pub_date

2000-02-01 00:00:00

pages

543-58

issue

5-6

eissn

1042-8194

issn

1029-2403

pii

I308J991149

journal_volume

36

pub_type

杂志文章
  • Non-Hodgkin lymphoma in Chile: a review of 207 consecutive adult cases by a panel of five expert hematopathologists.

    abstract::The distribution of subtypes of non-Hodgkin lymphoma (NHL) in Latin America is not well known. This Chilean study included 207 consecutive cases of NHL diagnosed at five cancer centers in the capital, Santiago, and one center in Viña del Mar. All cases were reviewed and classified independently by five expert hematopa...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究,评审

    doi:10.3109/10428194.2012.654471

    authors: Cabrera ME,Martinez V,Nathwani BN,Muller-Hermelink HK,Diebold J,Maclennan KA,Armitage J,Weisenburger DD

    更新日期:2012-07-01 00:00:00

  • Fine-Needle Aspiration Cytology and Immunocytochemistry of Abdominal Non-Hodgkin's Lymphomas.

    abstract::The cytomorphology and immunologic characteristics of cells obtained by fine-needle aspiration biopsy of 34 consecutive patients with abdominal lymphomas were analyzed. Nineteen patients had no previous diagnosis, while 15 had previously known or suspected lymphomas. On cytology 21 high-grade and 13 low-intermediate-g...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428198909042461

    authors: Liliemark J,Tani E,Christensson B,Svedmyr E,Skoog L

    更新日期:1989-01-01 00:00:00

  • Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3-5 October 2012.

    abstract::One hundred and seventy-five hemato-oncologists and nuclear medicine specialists from 23 countries joined the 2-day 4th International Workshop on Positron Emission Tomography in Lymphoma held in October 2012. The meeting was under the auspices of the European Lymphoma Institute, the Lymphoma Study Association (LYSA) a...

    journal_title:Leukemia & lymphoma

    pub_type:

    doi:10.3109/10428194.2013.802784

    authors: Meignan M,Barrington S,Itti E,Gallamini A,Haioun C,Polliack A

    更新日期:2014-01-01 00:00:00

  • Techniques for detection of minimal residual disease.

    abstract::Analysis of leukemia-specific and leukemia-associated markers following standard or high-dose treatments is crucial in order to evaluate the efficacy of therapeutic strategies. During the last decade, several techniques have been proposed and used for detecting minimal residual disease (MRD). Each approach is characte...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199509075308

    authors: Carlo-Stella C,Mangoni L,Dotti GP,Rizzoli V

    更新日期:1995-01-01 00:00:00

  • Acute myeloid leukemia outcome: role of nucleotide excision repair polymorphisms in intermediate risk patients.

    abstract::In acute myeloid leukemia (AML), cytogenetics predicts treatment outcome for the favorable and poor subgroups but not for the intermediate subgroup. Polymorphisms within the nucleotide excision repair (NER) pathway may lead to interindividual differences in DNA repair capacity, influencing outcome. We studied the role...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190903582804

    authors: Strom SS,Estey E,Outschoorn UM,Garcia-Manero G

    更新日期:2010-04-01 00:00:00

  • The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma.

    abstract::Adult T-cell leukemia/lymphoma (ATL) is frequently a very aggressive malignancy with a poor survival despite aggressive multiagent chemotherapy. The combination of the antiretroviral drug zidovudine (AZT) and interferon alpha (IFNalpha) has been reported to induce remissions in patients with ATL. The purpose of this s...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.3109/10428190109057927

    authors: White JD,Wharfe G,Stewart DM,Maher VE,Eicher D,Herring B,Derby M,Jackson-Booth PG,Marshall M,Lucy D,Jain A,Cranston B,Hanchard B,Lee CC,Top LE,Fleisher TA,Nelson DL,Waldmann TA

    更新日期:2001-01-01 00:00:00

  • Case-control study on concentrations of organohalogen compounds and titers of antibodies to Epstein-Barr virus antigens in the etiology of non-Hodgkin lymphoma.

    abstract::A rapid increase in incidence of non-Hodgkin lymphoma (NHL) has been reported from many countries. Exposure to certain pesticides and organochlorines has been shown to be risk factors. Epstein-Barr virus (EBV) is a human herpesvirus that has been associated with some subgroups of NHL, such as Burkitt lymphoma and lymp...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190109099322

    authors: Hardell E,Eriksson M,Lindström G,Van Bavel B,Linde A,Carlberg M,Liljegren G

    更新日期:2001-08-01 00:00:00

  • In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia; relation to plasma concentrations and protein binding.

    abstract::Since etoposide interacts with the nuclear enzyme topoisomerase II, the drug concentrations in the malignant cells during chemotherapy may have clinical correlates. Plasma protein binding of etoposide is extensive (94%) and alterations of the non-proteinbound fraction affect pharmacokinetic behavior of the drug. The p...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199309148555

    authors: Liliemark EK,Liliemark J,Pettersson B,Gruber A,Björkholm M,Peterson C

    更新日期:1993-07-01 00:00:00

  • A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia.

    abstract::In order to determine the efficacy of the antifibrinolytic agent tranexamic acid (TA) in reducing bleeding and platelet transfusions during the treatment of acute myeloid leukemia (AML), we conducted a randomized placebo-controlled double-blind study. Patients with AML undergoing induction or postremission consolidati...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.3109/10428199509059668

    authors: Shpilberg O,Blumenthal R,Sofer O,Katz Y,Chetrit A,Ramot B,Eldor A,Ben-Bassat I

    更新日期:1995-09-01 00:00:00

  • Non-Hodgkin's lymphoma presenting as anasarca: probably mediated by tumor necrosis factor alpha (TNF-alpha).

    abstract::Two patients presented with anasarca, fevers and sweats. Subsequent evaluation revealed aggressive lymphoproliferative disease. Both patients were treated with CHOP chemotherapy. One patient responded with spontaneous, vigorous diuresis and complete resolution of the edema. She relapsed two months later with recurrent...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190009087034

    authors: Jillella AP,Day DS,Severson K,Kallab AM,Burgess R

    更新日期:2000-07-01 00:00:00

  • Patients with activated B-cell like diffuse large B-cell lymphoma in high and low infectious disease areas have different inflammatory gene signatures.

    abstract::Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with an association with inflammation and viral infections. We hypothesize that environmental factors may be involved in the pathogenesis of DLBCL. In this study, we compared gene expression profiles of lymph node tissues from patients with DLBCL from tw...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.738365

    authors: Högfeldt T,Bahnassy AA,Kwiecinska A,Osterborg A,Tamm KP,Porwit A,Zekri AR,Lundahl J,Khaled HM,Mellstedt H,Moshfegh A

    更新日期:2013-05-01 00:00:00

  • Abnormal expression of CD66a promotes proliferation and inhibits apoptosis of human leukemic B cells in vitro.

    abstract::The aberrant expression of myeloid antigen CD66 on acute B-lymphoblastic leukemia (B-ALL) cells is a well-documented phenomenon. CD66a is a major subtype of the CD66 family which plays a dual role in different cancers, and the contradictory effect may depend on the isoform ratio of CD66a-4L to CD66a-4S. Although the a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2014.913287

    authors: Zhao W,Zhang Y,Liu D,Zhong L,He Q,Zhao Y

    更新日期:2015-01-01 00:00:00

  • Response to hyperfractionated accelerated radiotherapy in chemotherapy-refractory non-Hodgkin lymphoma.

    abstract::Patients with chemotherapy-refractory non-Hodgkin lymphoma (NHL) have a poor prognosis with a median overall survival (OS) of only 10 months. To investigate the role of radiotherapy (RT) in such patients, we conducted a retrospective review of 17 patients with biopsy-proven refractory NHL who received hyperfractionate...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1719096

    authors: Kim DW,Lee G,Lee H,Mahal AR,Lam MB,Ng AK

    更新日期:2020-06-01 00:00:00

  • Is there a difference in childhood T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma?

    abstract::To distinguish the similarities or differences between T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL), we retrospectively analyzed the clinical, immunophenotypic, cytogenetic, and molecular characteristics in 37 children diagnosed between December 1990 and December 2003. Compara...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701509772

    authors: Uyttebroeck A,Vanhentenrijk V,Hagemeijer A,Boeckx N,Renard M,Wlodarska I,Vandenberghe P,Depaepe P,De Wolf-Peeters C

    更新日期:2007-09-01 00:00:00

  • Bezafibrate and medroxyprogesterone acetate target resting and CD40L-stimulated primary marginal zone lymphoma and show promise in indolent B-cell non-Hodgkin lymphomas.

    abstract::B cell non-Hodgkin lymphomas (B-NHLs) are the most common adult hematological cancers and many remain incurable. Development of chemotherapy regimens is confounded by the prevalence of B-NHL in older, frailer patients and the chemo-protective tumor microenvironment. Although biological therapies such as rituximab have...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2014.939962

    authors: Hayden RE,Kussaibati R,Cronin LM,Pratt G,Roberts C,Drayson MT,Bunce CM

    更新日期:2015-04-01 00:00:00

  • Regulation of hematopoiesis by microvascular endothelium.

    abstract::The bone marrow microenvironment is a complex three dimensional structure where hematopoietic stem cells proliferate, mature, migrate into the sinusoidal space, and enter the circulation in an exquisitely regulated fashion. Stromal cells within the BM microenvironment provide a suitable environment for self-renewal, p...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199709058305

    authors: Rafii S,Mohle R,Shapiro F,Frey BM,Moore MA

    更新日期:1997-11-01 00:00:00

  • Therapy related myelodysplastic syndrome and leukemia with no "unfavourable" cytogenetic findings have a good response to intensive chemotherapy: a report on 15 cases.

    abstract::We treated 15 patients with therapy related acute nonlymphocytic leukemia (tANLL) or therapy related myelodysplastic syndrome (tMDS) who had no rearrangements of chromosomes 5 and/or 7 or complex cytogenetic rearrangements by intensive chemotherapy. The median age was 43 years. Seven patients had one of the "specific"...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199109068114

    authors: Fenaux P,Laï JL,Quiquandon I,Preudhomme C,Dupriez B,Facon T,Lorthois C,Lucidarme D,Bauters F

    更新日期:1991-01-01 00:00:00

  • Treatment of Philadelphia Chromosome Positive (Ph +) Chronic Myelogenous Leukemia in Blast Crisis and Ph + Acute Leukemia with High Dose Cytosine Arabinoside (HDARAC).

    abstract::High dose cytosine arabinoside (HDARAC) was administered to eleven patients in the blastic phase of Philadelphia (Ph) chromosome positive chronic myelogenous leukemia (CML). Four patients presented in blastic phase and in seven patients blastic transformation had evolved from a previous chronic phase. All patients had...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199109068053

    authors: Kempin S,Arlin Z,Berman E,Gee T,Mertelsmann R,Andreeff M,Kolitz J,Jhanwar S,Myers J,Clarkson B

    更新日期:1991-01-01 00:00:00

  • Chronic lymphocytic leukemia complicated by plasmacytoma originating from different clones.

    abstract::In a woman with chronic lymphocytic leukemia (CLL), a plasmacytoma developed on the back region after four years. CLL cases complicated with plasmacytoma are rare. In the present case, the plasmacytoma showed kappa cytoplasmic immunoglobulin (Ig), and the CLL showed gamma lambda surface Ig. To reveal the clonal origin...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190009053555

    authors: Yahata N,Iwase O,Iwama H,Tauchi T,Kawanishi Y,Serizawa H,Ohyashiki K

    更新日期:2000-09-01 00:00:00

  • Mutations within the 5' region of FAS/CD95 gene in nodal diffuse large B-cell lymphoma.

    abstract::CD95 is a cell-surface receptor that mediates apoptosis. A possible association between CD95 mutations and extranodal diffuse large B-cell lymphomas (DLBCL) has been reported. To further elucidate this question, a mutation analysis within the 5' region and exon 9 of CD95 was performed in a series of 66 DLBCL patients,...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701230858

    authors: Scholl V,Stefanoff CG,Hassan R,Spector N,Renault IZ

    更新日期:2007-05-01 00:00:00

  • The expression of anamorsin in diffuse large B cell lymphoma: possible prognostic biomarker for low IPI patients.

    abstract::Anamorsin is a cell-death-defying factor, which was originally isolated as a molecule that conferred resistance to apoptosis induced by growth factor starvation. In order to evaluate anamorsin expression levels in malignant lymphoma, we immunostained paraffin-embedded sections with anti-anamorsin monoclonal antibodies...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701713697

    authors: Shizusawa T,Shibayama H,Murata S,Saitoh Y,Sugimoto Y,Matsumura I,Ogawa H,Sugiyama H,Fukuhara S,Hino M,Kanamaru A,Yamauchi A,Aozasa K,Kanakura Y

    更新日期:2008-01-01 00:00:00

  • Diagnostic imaging in the evaluation of renal lymphoma.

    abstract::Renal lymphoma usually is a manifestation of disseminated disease and often is asymptomatic. Occasionally, the kidney(s) may be the major or only demonstrable site of disease, which may then present with a variety of urologic symptoms. The imaging studies should be tailored according to the presenting symptoms and pri...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199409114138

    authors: Eisenberg PJ,Papanicolaou N,Lee MJ,Yoder IC

    更新日期:1994-12-01 00:00:00

  • Acute trilineage leukemia with monosomy of chromosome 7 following an acute promyelocytic leukemia.

    abstract::We describe an 8 year old boy who had received chemotherapy for an acute promyelocytic leukemia and developed a secondary leukemia 27 months after the diagnosis of this first malignancy. Blasts cells were positive for cytoplasmic markers CD22, CD3 and myeloperoxidase. Cell surface T and myeloid-associated markers were...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199909050968

    authors: Felice MS,Rossi J,Gallego M,Zubizarreta PA,Cygler AM,Alfaro E,Sackmann-Muriel F

    更新日期:1999-07-01 00:00:00

  • DNA ploidy analysis as an adjunct for the detection of relapse in B-lineage acute lymphoblastic leukemia.

    abstract::Detection of relapse in acute lymphoblastic leukemia (ALL) is essential for proper management. However, immunophenotypic detection of relapse by flow cytometry in B-lineage ALL can be confounded by several factors, including lack of a unique immunophenotype and modulation of aberrant phenotypes after treatment. We hyp...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701760052

    authors: Kenney B,Zieske A,Rinder H,Smith B

    更新日期:2008-01-01 00:00:00

  • Analysis of circulating tumor DNA by targeted ultra-deep sequencing across various non-Hodgkin lymphoma subtypes.

    abstract::Although targeted deep sequencing of cell-free DNA (cfDNA) was recently used to investigate tumor somatic mutations in particular subtypes of non-Hodgkin lymphomas (NHLs), the immense genetic heterogeneity across subtypes poses a hurdle to design a universal gene panel applicable for diverse subtypes of NHLs. We desig...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1573998

    authors: Shin SH,Kim YJ,Lee D,Cho D,Ko YH,Cho J,Park WY,Park D,Kim SJ,Kim WS

    更新日期:2019-09-01 00:00:00

  • Hepatitis C virus, B-cell proliferation and lymphomas.

    abstract::Accumulating evidence support a role for hepatitis C virus (HCV) in the pathogenesis of human lymphoproliferative disorders. Clonal expansions of B lymphocytes have been prevalently detected in the bone marrow, in the liver and in the peripheral blood of HCV-infected patients. Epidemiologic studies have associated HCV...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190290016845

    authors: Gasparotto D,De Re V,Boiocchi M

    更新日期:2002-04-01 00:00:00

  • Case 36: a difficult diagnosis in a patient with fever and progressive multi-organ failure.

    abstract::A man in late middle age presented with fever, systemic symptoms, raised inflammatory markers and anaemia of chronic disease. Despite two months of investigation, the diagnosis of a haematological malignancy was made only at autopsy. ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701342703

    authors: Gabriel IH,Chong N,Rice A,Negus R,Bain BJ

    更新日期:2007-07-01 00:00:00

  • A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia.

    abstract::CXCR4 directs chronic lymphocytic leukemia (CLL) trafficking within protective tissue niches, and targeting CXCR4 with plerixafor may enhance drug sensitivity. We performed a phase 1 dose escalation study of plerixafor (NCT00694590) with rituximab in 24 patients with relapsed/refractory CLL. Patients received rituxima...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.1080/10428194.2019.1643463

    authors: Andritsos LA,Byrd JC,Cheverton P,Wu J,Sivina M,Kipps TJ,Burger JA

    更新日期:2019-12-01 00:00:00

  • Three cases of primary cutaneous lymphoblastic lymphoma: microarray-based comparative genomic hybridization and gene expression profiling studies with review of literature.

    abstract::Lymphoblastic lymphoma (LBL) is a neoplasm of precursor B- or T-lymphocytes, and primary skin involvement is uncommon. The aim of the study was to review all reported primary cutaneous (PC)-LBLs and to examine three new cases to better characterize this neoplasm. Two of our patients showed a pre-B phenotype (PC-B-LBL)...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2011.618233

    authors: Vezzoli P,Novara F,Fanoni D,Gambini D,Balice Y,Venegoni L,Paulli M,Crosti C,Berti E

    更新日期:2012-10-01 00:00:00

  • Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation.

    abstract::The (1;19)(q23;p13) translocation, leading to the production of the E2A/PBX1 fusion transcript, is one of the most common translocations in pediatric B-lineage acute lymphoblastic leukemia (ALL). It was assumed to be associated with a poor clinical outcome, although intensive therapy and bone marrow transplantation ha...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500331261

    authors: Piccaluga PP,Malagola M,Rondoni M,Ottaviani E,Testoni N,Laterza C,Visani G,Pileri SA,Martinelli G,Baccarani M

    更新日期:2006-03-01 00:00:00